WLF backs Allergan off-label suit

Share this article:
Washington Legal Foundation (WLF) and three patient advocacy groups have filed a friend of the court brief in the District of Columbia federal court supporting a request by Allergan for a preliminary injunction to block the FDA from enforcing regulations and policies prohibiting the company from providing information to healthcare providers on an off-label Botox.

Allergan's complaint and request for injunction says that it is not seeking to communicate with consumers, but wants to give healthcare providers safety data on using Botox to treat spasticity in certain patients.

Allergan says that providing such information to healthcare professionals is against FDA regulations and federal government policies and makes a company vulnerable to criminal prosecution and civil penalties. The company claims that such policies and regulations violate the First Amendment's free speech provisions and are inconsistent with the Federal Food, Drug and Cosmetic Act.

The WLF brief says that the Allergan suit “squarely presents the question whether the First Amendment permits the federal government to ban truthful, accurate and non-misleading speech to physicians regarding off-label uses of FDA-approved prescription drugs.”

It notes that the importance, prevalence and value of off-label uses are well known to healthcare professionals.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?